https://www.selleckchem.com/pr....oducts/vorapaxar.htm
To analyze the risk factors of neurological function recovery and occurrence of cerebral hemorrhage transformation (HT) after recombinant tissue-type plasiminogen activator (re-PA) in patients with acute ischemic stroke (AIS). The 173 patients with AIS who received rt-PA thrombolysis in Changshu Hospital of Xuzhou Medical University from March, 2018 to January, 2020 were selected as research objects, and they were divided into HT group (46 cases) and non HT group (127 cases) according to whether HT occurred. The data such as gender, a